Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer-Reference-Cited by-同舟云学术

Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer

Published:2018-10 Issue: Volume:52 Page:16-25
ISSN:1044-579X
Container-title:Seminars in Cancer Biology
language:en
Short-container-title:Seminars in Cancer Biology

Author:

Dieci Maria Vittoria,Radosevic-Robin Nina,Fineberg Susan,van den Eynden Gert,Ternes Nils,Penault-Llorca Frederique,Pruneri Giancarlo,D’Alfonso Timothy M.,Demaria Sandra,Castaneda Carlos,Sanchez Joselyn,Badve Sunil,Michiels Stefan,Bossuyt Veerle,Rojo Federico,Singh Baljit,Nielsen Torsten,Viale Giuseppe,Kim Seong-Rim,Hewitt Stephen,Wienert Stephan,Loibl Sybille,Rimm David,Symmans Fraser,Denkert Carsten,Adams Sylvia,Loi Sherene,Salgado Roberto

Funder

Breast Cancer Research Foundation (BCRF)

CIBERONC

Publisher

Elsevier BV

Subject

Cancer Research

Reference49 articles.

1. Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review;Stanton;JAMA Oncol.,2016

2. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer;Denkert;J. Clin. Oncol.,2010

3. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without Carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers;Denkert;J. Clin. Oncol.,2015

4. Prognostic and predictive value of nanostring-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes;Lee;Breast Cancer Res. Treat.,2015

5. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study;Dieci;Ann. Oncol.,2014

Cited by 338 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic factors of patients with human epidermal growth factor receptor 2-positive breast cancer following neoadjuvant therapy: Development and validation of a predictive nomogram;Pathology - Research and Practice;2024-09

2. Non-genetic heterogeneity and immune subtyping in breast cancer: Implications for immunotherapy and targeted therapeutics;Translational Oncology;2024-09

3. Association of clinicopathologic and sonographic features with stromal tumor-infiltrating lymphocytes in triple-negative breast cancer;BMC Cancer;2024-08-12

4. PRECISE: Preoperative Radiation Therapy to Elicit Critical Immune Stimulating Effects – A Phase 2 Clinical Trial;International Journal of Radiation Oncology*Biology*Physics;2024-08

5. Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response;Nature Communications;2024-07-11